AIM
RIGL icon

Alambic Investment Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Alambic Investment Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-13,338
Closed -$364K – 574
2017
Q2 		$364K Sell
13,338
-450
-3% -$12.3K 0.04% 429
2017
Q1 		$456K Sell
13,788
-5,273
-28% -$134K 0.06% 426
2016
Q4 		$454K Buy
19,061
+2,310
+14% +$66.2K 0.08% 349
2016
Q3 		$615K Sell
16,751
-3,423
-17% -$98.1K 0.14% 245
2016
Q2 		$450K Sell
20,174
-7,116
-26% -$177K 0.11% 302
2016
Q1 		$568K Buy
27,290
+12,880
+89% +$318K 0.18% 199
2015
Q4 		$437K Buy
+14,410
New +$437K 0.26% 145

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alambic Investment Management's RIGL Position: Q3 2017 in Review

Alambic Investment Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2017, closing a stake of 13,338 shares — an estimated $364K sold.

Alambic Investment Management first reported a position in RIGL in Q4 2015 and held it in 7 quarters. The position peaked at $615K in Q3 2016. 108 funds tracked by Wall St. Rank hold RIGL as of Q3 2017.

  • Alambic Investment Management reported no remaining Rigel Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Alambic Investment Management sold 13,338 Rigel Pharmaceuticals shares in Q3 2017, an estimated $364K.
  • Alambic Investment Management first reported a position in Rigel Pharmaceuticals in Q4 2015 and held it in 7 quarters.
  • Alambic Investment Management's Rigel Pharmaceuticals position peaked at $615K in Q3 2016.
  • 108 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2017.

Based on Alambic Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.